|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Abbott Laboratories, of Abbott Park, Ill., said Phase II findings reported at the American Academy of Dermatology meeting in New York showed patients with moderate to severe chronic plaque psoriasis achieved significant and continued improvement in disease activity and quality of life over 24 weeks of treatment with Humira (adalimumab). Specifically, 64 percent of patients taking Humira 40 mg every other week achieved at least a 75 percent improvement in disease extent and severity after 24 weeks, and 42 percent on the same regimen had at least a 90 percent improvement in their disease.
o Acacia Research Corp., of Newport Beach, Calif., said its CombiMatrix ...
Related newspaper, magazine, and journal articles:
|